# Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Source: https://onco.cc/trials/nct06134232/  
OnCo record `nct06134232` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sipuleucel-T in prostate cancer, run by Dendreon, now recruiting.

## Summary

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T is a phase 2 interventional study registered as NCT06134232 by Dendreon, with 400 participants planned, started 2023-10-02 and due to reach its primary completion in 2031-12-31. Interventions recorded: Sipuleucel-T Injection. Conditions listed: Metastatic Castration-Resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06134232
- Phase: 2
- Setting: An Open -Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With PROVENGE ® and Boosted With A Single Infusion of Sipuleucel-T to Measure Immune Response
- Sponsor: Dendreon
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT06134232: https://clinicaltrials.gov/study/NCT06134232

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Sipuleucel-T](https://onco.cc/drugs/sipuleucel-t/)
- companies: [Dendreon](https://onco.cc/companies/dendreon/)

---
JSON: https://onco.cc/api/v1/entities/nct06134232.json